Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun:39 Suppl 1:104-112.
doi: 10.1002/hon.2844.

Optimizing CAR T cell therapy in lymphoma

David Qualls  1 , Gilles Salles  1
Affiliations
Review

Optimizing CAR T cell therapy in lymphoma

David Qualls et al. Hematol Oncol. 2021 Jun.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has significantly improved the outlook for patients with certain types of poor-risk lymphoma. Despite these advances, a majority of patients undergoing CAR T therapy will suffer progression or relapse of disease, and toxicity remains a concern. Additionally, the patients and disease subtypes that are most likely to benefit from CAR T have yet to be fully defined. Many ongoing trials are exploring novel CAR T approaches to address these concerns. In this review, we highlight some of the primary strategies and relevant studies aimed at improving the utility of CAR T therapy in lymphoma.

Keywords: cellular therapy; chimeric antigen receptor T cell; lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Locke FL , Ghobadi A , Jacobson CA , et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. https://doi.org/10.1016/S1470-2045(18)30864-7
    1. Schuster SJ , Bishop MR , Tam CS , et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56. https://doi.org/10.1056/nejmoa1804980
    1. Abramson JS , Palomba ML , Gordon LI , et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. https://doi.org/10.1016/S0140-6736(20)31366-0
    1. Crump M , Neelapu SS , Farooq U , et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. https://doi.org/10.1182/blood-2017-03-769620
    1. Vitale C , Strati P . CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10:849. https://doi.org/10.3389/fonc.2020.00849

MeSH terms

Substances

LinkOut - more resources